Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Work In Process (2022 - 2024)

Atara Biotherapeutics' Work In Process history spans 3 years, with the latest figure at $9.7 million for Q4 2024.

  • For Q4 2024, Work In Process rose 31.47% year-over-year to $9.7 million; the TTM value through Dec 2024 reached $9.7 million, up 31.47%, while the annual FY2024 figure was $9.7 million, 31.47% up from the prior year.
  • Work In Process reached $9.7 million in Q4 2024 per ATRA's latest filing, down from $12.3 million in the prior quarter.
  • In the past five years, Work In Process ranged from a high of $15.1 million in Q2 2024 to a low of $372000.0 in Q4 2022.
  • Average Work In Process over 3 years is $7.8 million, with a median of $7.4 million recorded in 2023.
  • Peak YoY movement for Work In Process: soared 1881.45% in 2023, then surged 31.47% in 2024.
  • A 3-year view of Work In Process shows it stood at $372000.0 in 2022, then skyrocketed by 1881.45% to $7.4 million in 2023, then soared by 31.47% to $9.7 million in 2024.
  • Per Business Quant, the three most recent readings for ATRA's Work In Process are $9.7 million (Q4 2024), $12.3 million (Q3 2024), and $15.1 million (Q2 2024).